Immuron Limited (AU:IMC) has released an update.
Immuron Limited, an Australian biopharmaceutical company, has filed a Form F-3 and ATM Prospectus with the U.S. SEC, allowing it to raise up to US$15 million in the United States over three years. Through an At-the-Market funding facility with H.C. Wainwright & Co., Immuron has the flexibility to issue shares at market prices up to approximately US$2 million, providing direct access to U.S. capital markets within ASX Listing Rules.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
